1.Dynorphin and enkephalin mRNAs in the rat forebrain by in situ hynridization histochmistry.
Korean Journal of Anatomy 1992;25(2):179-187
No abstract available.
Animals
;
Dynorphins*
;
Enkephalins*
;
Prosencephalon*
;
Rats*
;
RNA, Messenger*
3.Relationship of Longitudinal Extent of Hippocampal Sclerosis to Clinical Characteristics, Hippocampal Neuronal Cell Loss and Dynorphin-Immunoreactivity Patterns in Intractable Temporal Lobe Epilepsy with Hippocampal Sclerosis.
Jang Sung KIM ; Jung Sun KIM ; Sun Yong KIM ; Joong Seok SEO
Journal of Korean Epilepsy Society 1999;3(1):16-21
PURPOSE: In mesial temporal lobe epilepsy (TLE). Hippocampl sclerosis (HS) is a pathologic substrate and characterized by significant neuronal loss and band-like synaptic reorganization in dentate inner molecular layer (DGIML) og sclerotic hippocampus with either Timm`s staining or Dynorphin (Dyn)-immunohistochemical staining methods. Hippocampus has neuronal synaptic circuitries of both intralamellar and translamellar patterns, from which we may hypothesize that longitudinal extent of HS represents variable pathophysiologic implications of neuronal injury, ictogenesis and epileptogenesis in mesial TLE. We tested the hypothesis. METHODS: Eleven mesial TLE patients with HS on MRI were recruited from epilepsy surgery registry. Resected hippocampal slices were stained with Dyn immunohistochemical method. We classified them into cases with partial HS and thoes with extensive HS according to longitudinal HS extent,. Between the two groups, clinical characteristics of seizures or epilepaies, Hippocampal neuronal density and neuronal loss. and Dynimmunoreactivity (IR) patterns were compared and analyzed. Dyn-IR pattern was classified as presence or absence of DGIML band and of CA3-IR. RESULTS: Nine cases showed extensive HS whereas two were classified as partial HS. There appeared no significant differences in clinical characteristics, neuronal density, neuronal loss and Dyn-IR patterns between those with extensive and partial HS. CONCLUSION: In this study, we could not prove the hypothesis that difference in HS extend on MRI may represent distinctive variabliity in severity of hippocampal neuronal injury and in ictiogenetic or epileptogenetic pathophysiology.
Dynorphins
;
Epilepsy
;
Epilepsy, Temporal Lobe*
;
Hippocampus
;
Humans
;
Magnetic Resonance Imaging
;
Neurons*
;
Sclerosis*
;
Seizures
;
Temporal Lobe*
4.The protection of scorpion venom derived activity peptide against the change of dynorphin in the early Parkinson's disease rats.
Dong-mei WANG ; Dan ZHAO ; Sheng-ming YIN ; Dong AN ; Wei CHEN ; De-qin YU ; Hong XU ; Jie ZHAO ; Wan-qin ZHANG ; Yu-xiang TIAN
Chinese Journal of Applied Physiology 2015;31(2):120-122
Animals
;
Dynorphins
;
metabolism
;
Parkinson Disease
;
drug therapy
;
metabolism
;
Peptides
;
pharmacology
;
Rats
;
Scorpion Venoms
;
pharmacology
5.Regulation of DREAM Expression by Group I mGluR.
Jinu LEE ; Insook KIM ; So Ra OH ; Suk Jin KO ; Mi Kyung LIM ; Dong Goo KIM ; Chul Hoon KIM
The Korean Journal of Physiology and Pharmacology 2011;15(2):95-100
DREAM (downstream regulatory element antagonistic modulator) is a calcium-binding protein that regulates dynorphin expression, promotes potassium channel surface expression, and enhances presenilin processing in an expression level-dependent manner. However, no molecular mechanism has yet explained how protein levels of DREAM are regulated. Here we identified group I mGluR (mGluR1/5) as a positive regulator of DREAM protein expression. Overexpression of mGluR1/5 increased the cellular level of DREAM. Up-regulation of DREAM resulted in increased DREAM protein in both the nucleus and cytoplasm, where the protein acts as a transcriptional repressor and a modulator of its interacting proteins, respectively. DHPG (3,5-dihydroxyphenylglycine), a group I mGluR agonist, also up-regulated DREAM expression in cortical neurons. These results suggest that group I mGluR is the first identified receptor that may regulate DREAM activity in neurons.
Calcium
;
Cytoplasm
;
Dynorphins
;
Methoxyhydroxyphenylglycol
;
Neurons
;
Potassium Channels
;
Presenilins
;
Proteins
;
Receptors, Metabotropic Glutamate
;
Up-Regulation
6.The Gene Expression of Dynorphin, Enkephalin, c-Fos in the Neuropathic Rat.
Neung Hee HAN ; Won Hyung LEE ; Won Jae HWANG ; Sug Hwa YOON ; Yong Sup SHIN ; Soo Chang SON ; Hye Ja KIM ; Sae Jin CHOI ; Kyu LIM ; Byung Doo HWANG
Korean Journal of Anesthesiology 1996;31(3):293-303
BACKGROUND: We studied the time course of gene expression of dynorphin, enkephalin, c-fos, and the changes of allodynia, and the effect of chemical sympathectomy on the gene expression and allodynia in neuropathic rat. METHODS: In two groups of rat (Sprague-Dawley), the left L5 and L6 spinal nerves were tight ligated. In gene expression group (N=25), behavioral tests for mechanical allodynia and cold allodynia were perfomed for the next two weeks. After the test of allodynia, the expression of dynorphin, enkephalin, c-fos were assessed by Northern blot hybridization. In chemical sympathectomy group (N=16), after chemical sympathectomy (guanethidine 70 mg/kg intraperitoneally, from postoperative 7 days to 9 days), the changes of allodynia and the gene expression of enkephalin, c-fos were tested. RESULTS: Mechanical allodynia and cold allodynia was developed on the postoperative 3, 5, 7, 14 days. Preprodynorphin mRNA expression was reached peak level at the postoperative 8 hrs, sustained increase by the postoperative 3 days, but preproenkephalin mRNA expression increased slightly after operation. c-Fos mRNA expression was increased immediately at the postoperative 30 min, 1 hr, returned to normal level thereafter, and increased again on the postoperative 3, 5, 7 days that neuropathic pain was developed. Mechanical allodynia and cold allodynia were decreased by chemical sympathectomy. The increased c-fos mRNA expression and pain at postoperative 7 days was reduced by chemical sympathectomy. CONCLUSION: These results suggest that the transient gene expression of dynorphin and c-fos after tight ligation of L5 and L6 spinal nerves induces the development neuropathic pain, and late c-fos expression is related to neuropathic pain.
Animals
;
Blotting, Northern
;
Dynorphins*
;
Enkephalins*
;
Gene Expression*
;
Hyperalgesia
;
Ligation
;
Neuralgia
;
Rats*
;
RNA, Messenger
;
Spinal Nerves
;
Sympathectomy, Chemical
7.Effects of an Opiate Receptor Antagonist Naloxone on Endotoxic Shock and Tumorigenesis.
Tai You HA ; Yoo Seung KO ; Sun Rock MOON
Korean Journal of Immunology 1997;19(1):91-106
Septic shock is one of the leading cause of death in hospitalized patients and mortality rates of up to 50 % have been reported. Despite all efforts, no regimen today seems to be successful in the treatment of septic shock. The endogenous opioid system (EOS) includes three major families of peptides: dynorphins, endorphins and enkephalins. Several lines of evidence indicate that EOS is implicated in the pathophysiology of anaphylactic and endotoxic shock. An opioid receptor blocker naloxone has been used extensively in studies for the role of EOS or endogenous opiod peptides (EOP). However, there have been few, if any, detailed investigative studies regarding the effect of naloxone on TNF-a production and the lethality in response to endotoxin, and tumorigenesis. ...continue...
Carcinogenesis*
;
Cause of Death
;
Dynorphins
;
Endorphins
;
Enkephalins
;
Humans
;
Melanoma
;
Mortality
;
Naloxone*
;
Nitric Oxide
;
Peptides
;
Receptors, Opioid*
;
Shock, Septic*
8.The effects of kainate-induced Seizure on the Opioid Peptide Gene Expression in Rat Hippocampus.
Kun Woo PARK ; Min Kyu PARK ; Byung Jo KIM ; Sung Bum KO ; Youn Hee KANG ; Dae Hie LEE
Journal of the Korean Neurological Association 1994;12(4):614-622
In the rat hippocampal formation, the time-course and dose-response of the expression of enkephalin and dynorphin gene were examined after kainate (KA) treatment with in situ hybridization histochemistry. The KA induced enkephalin and dynorphin mRNA expression in hippocampus occurred mainly in the dentate gyrus. The enkephalin mRNA expression appeared at 3hour after KA injection, increased dramatically at 6hour, and then decreses. At 24hour after KA injection, the expression of enkephalin mRNA disappeared. The dynorphin mRNA expression appeared at once after injection and increased dramatically at 3hour. Unexpectedly at 6hour after injection, the expression was decreased, and then increased less than the 3hour expression. The increased pattern persisted to 24hour after injection. Unexpected result was also encounted in the experiment of KA dose-response of enkephalin mRNA and dynorphin mRNA. In the hippocampal formation, in contrast with other areas, low dosage (8mg/kg) of KA induced more significant expression of both genes than high dosage (16mg/kg) of KA.
Animals
;
Dentate Gyrus
;
Dynorphins
;
Enkephalins
;
Gene Expression*
;
Hippocampus*
;
In Situ Hybridization
;
Kainic Acid
;
Opioid Peptides*
;
Rats*
;
RNA, Messenger
;
Seizures*
9.Comprehensive Review on Kisspeptin and Its Role in Reproductive Disorders.
Holly CLARKE ; Waljit S DHILLO ; Channa N JAYASENA
Endocrinology and Metabolism 2015;30(2):124-141
Kisspeptin has recently emerged as a key regulator of the mammalian reproductive axis. It is known that kisspeptin, acting centrally via the kisspeptin receptor, stimulates secretion of gonadotrophin releasing hormone (GnRH). Loss of kisspeptin signaling causes hypogonadotrophic hypogonadism in humans and other mammals. Kisspeptin interacts with other neuropeptides such as neurokinin B and dynorphin, to regulate GnRH pulse generation. In addition, a growing body of evidence suggests that kisspeptin signaling be regulated by nutritional status and stress. Kisspeptin may also represent a novel potential therapeutic target in the treatment of fertility disorders. Early human studies suggest that peripheral exogenous kisspeptin administration stimulates gonadotrophin release in healthy adults and in patients with certain forms of infertility. This review aims to concisely summarize what is known about kisspeptin as a regulator of reproductive function, and provide an update on recent advances within this field.
Adult
;
Dynorphins
;
Fertility
;
Gonadotropin-Releasing Hormone
;
Humans
;
Hypogonadism
;
Hypothalamus
;
Infertility
;
Kisspeptins
;
Mammals
;
Neurokinin B
;
Neuropeptides
;
Nutritional Status
;
Axis, Cervical Vertebra
10.Dynorphin A (1-17) was Selective tomicro-Opioid Receptor in Agonist-Stimulated 35S GTPgammaS Binding in Cortical and Thalamic Membranes of Monkey.
Heeseung LEE ; Sung Ae LEE ; Sin Young KANG ; Dong Yeon KIM ; Chi Hyo KIM
Korean Journal of Anesthesiology 2005;48(4):412-416
BACKGROUND: Dynorphin A (1-17) is conceived as an endogenous opioid peptide with a high degree of selectivity forkappa- opioid receptor even though it has been reported to sometimes act like amicro- opioid agonist. The aim of this study was to investigate [35S] GTPgammaS binding stimulated activation by dynorphin A (1-17) in the cerebral and thalamic membranes of a rhesus monkey. METHODS: The rhesus monkey (Macaca mulatta, male, n = 1) was euthanized for the preparation of the cerebral and thalamic membranes. Protein concentrations were determined by the Bradford method. In the dynorphin A (1-17)-stimulated [35S] GTPgammaS binding dose-response curve, EC50 (effective concentration 50 nM) and maximum stimulation (% over basal) were determined in the absence or presence of themicro-andkappa-opioid receptor antagonists naloxone (20 nM) and norbinaltorphimine (nor-BNI, 3 nM), respectively. E2078-stimulated [35S] GTPgammaS binding was also determined in the absence or presence ofmicro-andkappa-opioid receptor antagonists in the cortical membrane and compared with dynorphin A (1-17). RESULTS: Values of EC50 and maximum stimulation of dynorphin A (1-17)-stimulated [35S] GTPgammaS binding were as follows: cortex (474 nM/32.0%) and thalamus (423 nM/45.3%). Nor-BNI (3 nM) did not antagonize dynorphin A (1-17)-stimulated [35S] GTPgammaS binding at all in cortical or thalamic membrane, but naloxone (20 nM) produced a 12.2 fold rightward shift of the dynorphin A (1-17)-stimulated [35S] GTPgammaS binding dose-response curve in the thalamic membrane. The EC50 and the maximum stimulation of E2078-stimulated [35S] GTPgammaS binding were 65.6 nM and 22.7%, respectively. In E2078-stimulated [35S] GTPgammaS binding, the dose-response curve was antagonized not by nor-BNI but by naloxone but in the cortical membrane (a 14.2 times rightward shift). CONCLUSIONS: Dynorphin A (1-17) is selective formicro-opioid receptor in agonist-stimulated [35S] GTPgammaS binding in the cortical and thalamic membranes of rhesus monkey.
Dynorphins*
;
Guanosine 5'-O-(3-Thiotriphosphate)*
;
Haplorhini*
;
Humans
;
Macaca mulatta
;
Male
;
Membranes*
;
Naloxone
;
Opioid Peptides
;
Receptors, Opioid
;
Thalamus